Search global stocks & ETFs...Ctrl K
Learn Mode
MRNA
Stock Profile
07-30
Recommended Metric
Score Card
Explore Scores Tab
1.86
Bad
Valuation Score
Key Score
2.00
Bad
Management
1.00
Very Bad
Growth
1.00
Very Bad
Profitability
4.00
Good
Fin. Health
3.00
Average
Dividends
--
--
Analyst
1.00
Very Bad
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$79.76
Baseline
High
$141.75
▲
77.72%
Avg
$49.02
▼
-38.54%
Low
$21.21
▼
-73.41%
Analyst Ratings based on 30 Analysts
Strong Buy
000%
Buy
413%
Hold
1963%
Sell
413%
Strong Sell
310%
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The company is headquartered in Cambridge, Massachusetts and currently employs 4,700 full-time employees. The company went IPO on 2018-12-07. The company is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). The company also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. The company has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).Read More